Brief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
27/08/2026 21:34
BRIEF-Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™ Aug 27 (Reuters) - Outlook Therapeutics Inc OTLK.O:
OUTLOOK THERAPEUTICS APPOINTS KEVIN LUNDQUIST AS CHIEF FINANCIAL OFFICER AS IT PREPARES FOR U.S. COMMERCIAL LAUNCH OF LYTENAVA™
OUTLOOK THERAPEUTICS - LAWRENCE KENYON TO STEP DOWN AS CFO EFFECTIVE SEPTEMBER 1, 2026
Source text: ID:nGNX67wSMX
Further company coverage: OTLK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce